The Frc–Oxc Pathway in Microbial Oxalate Metabolism and Its Therapeutic Potential for Calcium Oxalate Kidney Stones

Abstract

Gut microbial oxalate degradation has emerged as a potential strategy for reducing hyperoxaluria and calcium oxalate kidney stone risk. Among microbial oxalate-degrading systems, the OxlT–Frc–Oxc pathway is one of the best-characterized routes because it couples oxalate catabolism to membrane transport and bacterial energy conservation. Frc activates oxalate by transferring CoA from formyl-CoA to oxalate, whereas Oxc, a thiamine-diphosphate-dependent enzyme, decarboxylates oxalyl-CoA to formyl-CoA and CO₂, allowing pathway cycling. Published sequence-mining studies have identified more than 1300 putative OXC homologs distributed across seven major clusters, indicating that oxalate-degradation capacity is broader than Oxalobacter formigenes alone. However, clinical translation remains inconsistent. Recent human colonization and microbiome studies show that O. formigenes administration can reduce urinary oxalate in some individuals, but response depends on colonization stability, baseline oxalate-degrading gene abundance, diet, antibiotic exposure, and intestinal niche conditions. This review synthesizes biochemical, structural, functional, ecological, and therapeutic evidence for the Frc–Oxc pathway and discusses why gene carriage alone does not guarantee in vivo oxalate degradation. Finally, the Oxalate Niche Index (ONI) is considered as a conceptual framework for integrating genetic capacity, pathway activity, niche permissiveness, ecological persistence, and inhibitory pressure in future microbiome-based strategies for hyperoxaluria and calcium oxalate kidney stone disease.

1. Introduction

Oxalate accumulation contributes to hyperoxaluria, calcium oxalate nephrolithiasis, and kidney injury, and because mammals lack an oxalate-catabolic pathway, gut microbes provide the primary sink limiting oxalate absorption [1,2,3]. The best-characterized microbial route is the formyl-CoA transferase–oxalyl-CoA decarboxylase (Frc–Oxc) system, in which Frc/Oxc couple oxalate metabolism to OxlT-mediated oxalate/formate exchange and proton-motive-force generation, motivating microbiome-based strategies to lower systemic oxalate burden [4,5,6]. These mechanistic insights have driven efforts to restore oxalate degradation through probiotics and recolonization strategies, with the assumption that the mere presence of oxalate-degrading microbes will reduce systemic oxalate levels and protect human health.

However, clinical translation has been inconsistent. Probiotic and synbiotic interventions have failed to deliver consistent reductions in urinary oxalate or stone recurrence, revealing a critical barrier in effective therapeutic application [7,8]. Oxalobacter formigenes (a common intestinal oxalate-degrading bacterium) colonization varies, is often transient, and is antibiotic-sensitive [9,10], while supplementation effects are heterogeneous and often strongest in low-baseline individuals [11,12]. Furthermore, metagenomic studies demonstrate that frc/oxc carriage does not consistently predict in vivo oxalate degradation, revealing a persistent gap between genetic potential and measurable function [13,14]. Collectively, these findings have fueled an ongoing debate: Is O. formigenes depletion a causal factor in hyperoxaluria, or just a sign of a non-permissive gut niche formed by diet, bile acids, inflammation, and community competition [15,16]?

To address these challenges, the field has changed from taxon-centric to ecological thinking. It has come to understand that the efficacy of a probiotic depends on the recipient gut environment and metabolic niche rather than the specific strain employed [11,12,17]. In this situation, the proposed Oxalate Niche Index (ONI, discussed further in the future perspectives in Section 6.5) may serve as a conceptual framework for integrating niche permissiveness with pathway-related capacity. Rather than treating oxalate degradation as a static property of bacterial presence alone, this perspective highlights that meaningful Frc–Oxc activity depends on favorable transport energetics, regulatory activation, and ecological persistence within the gut. This review focuses scientifically on the biochemical, structural, functional, ecological, and therapeutic relevance of the Frc–Oxc pathway in microbial oxalate metabolism, with particular emphasis on hyperoxaluria and calcium oxalate kidney stone disease rather than all forms of human calculi or urolithiasis. In addition, the proposed Oxalate Niche Index (ONI) is discussed as a conceptual framework for explaining variability in oxalate-targeted microbiome therapy.

Clinical Background: Oxalate Homeostasis and Calcium Oxalate Stone Formation

Oxalate homeostasis in humans is controlled by the balance among endogenous oxalate production, dietary oxalate intake, intestinal absorption, microbial degradation, and renal excretion [3,18]. Because mammals do not possess an enzymatic pathway for oxalate degradation, oxalate acts largely as a metabolic end product that must either be eliminated by the kidneys or degraded by intestinal microorganisms before absorption [19,20]. This makes the gut–kidney axis clinically important in hyperoxaluria and calcium oxalate kidney stone disease.

Human oxalate originates from both endogenous and exogenous sources. Endogenous oxalate is generated mainly through hepatic metabolism of glyoxylate, glycolate, glycine, hydroxyproline, and ascorbate-derived intermediates [3,21]. In primary hyperoxaluria, inherited defects in glyoxylate metabolism cause excessive endogenous oxalate production, resulting in marked hyperoxaluria, calcium oxalate deposition, nephrolithiasis, nephrocalcinosis, and progressive kidney injury [22,23]. Exogenous oxalate is derived from the diet, especially oxalate-rich foods such as spinach, rhubarb, nuts, cocoa, tea, and some leafy vegetables [18,24,25]. However, the clinical effect of dietary oxalate depends not only on oxalate intake, but also on intestinal solubility, calcium and magnesium availability, gut transit, fat absorption, microbiota composition, and intestinal absorptive status [26,27,28].

In the gastrointestinal tract, soluble oxalate can be absorbed across the intestinal epithelium and later excreted in urine [21]. Dietary calcium and magnesium can bind oxalate in the gut lumen, forming poorly soluble complexes and thereby reducing intestinal oxalate absorption [18,26]. In contrast, low dietary calcium intake, fat malabsorption, bile acid disturbances, intestinal inflammation, bariatric surgery, or disruption of oxalate-degrading microbiota can increase the soluble oxalate pool and promote enteric hyperoxaluria [23,29,30]. Under these conditions, more oxalate becomes available for intestinal absorption, increasing urinary oxalate excretion and calcium oxalate supersaturation [3,31].

Renal excretion is the principal route for removing absorbed oxalate from the body. Because urinary oxalate concentration strongly influences calcium oxalate supersaturation, even moderate increases in urinary oxalate can increase stone risk [3,21,24]. Calcium oxalate stone formation is a multistep process involving urinary supersaturation, crystal nucleation, crystal growth, aggregation, and retention within the kidney [32]. Additional urinary and host factors, including low urine volume, hypercalciuria, hypocitraturia, reduced magnesium, altered urinary macromolecules, Randall’s plaque formation, epithelial injury, and inflammation, can further influence crystal retention, stone growth, and recurrence risk, supporting the need for long-term multimodal prevention strategies [32,33].

The gut microbiota may modify this clinical process by degrading luminal oxalate before absorption [19,20]. Oxalate-degrading bacteria, particularly those carrying the OxlT–Frc–Oxc system, can convert oxalate into formate and CO₂, thereby reducing the intestinal oxalate pool and potentially lowering urinary oxalate burden [19,20]. However, microbial protection is not determined only by the presence of oxalate-degrading taxa or genes. Effective oxalate degradation requires pathway expression, substrate availability, suitable intestinal conditions, active transport, and colonization stability [34,35]. This clinical background provides the rationale for focusing on the Frc–Oxc pathway as a therapeutic target, while also explaining why probiotic outcomes may vary among patients with different dietary, microbial, metabolic, and disease contexts [17,36].

2. Biochemical Pathway of Oxalate Degradation Involving Frc and Oxc

2.1. Overview of the Oxalate Catabolic Pathway (OCP)

One of the major microbiological recycling processes is bacterial oxalate degradation, in which oxalate is converted to formate and CO₂, thereby completing the consecutive reactions of frc and oxc [37]. This two-step anaerobic route is a crucial metabolic trait of certain symbionts of the gut, including O. formigenes (Figure 1A,B) [37]. By constantly ingesting luminal oxalate, these microbes play a role in intestinal and general oxalate homeostasis maintenance [38]. Frc–Oxc pathway has diverse ecological purposes outside the gut [39,40].

The frc–oxc genes can be arranged in an operon, facilitating their coordinated expression during oxalate degradation [41,42]. Their transcription is regulated by environmental conditions like pH and availability of oxalate [4]. The oxalate comes into the cell via the OxlT antiporter, and then Frc converts it to oxalyl-CoA, and Oxc to formyl-CoA and CO₂ [43,44]. Proteomic analyses indicate that oxalotrophic bacteria highly upregulate Frc and Oxc in reaction to oxalate; e.g., one of the Azospirillum species is able to degrade whole calcium oxalate in 72 h with significant enhancement in both enzymes [44]. Together, these findings suggest that coordinated expression of OxlT, Frc, and Oxc is essential for efficient oxalate degradation under conditions where oxalate is available (

Table 1. Key Steps in the Oxalate Degrading Pathway (ODP) Mediated by Frc and Oxc.

Step	Enzyme	Substrate	Product	Cofactor/Requirement	Reference
Uptake/Efflux	Oxalate/formate antiporter (OxlT; MFS/OFA family)	Oxalate2− (extracellular) + Formate− (intracellular)	Oxalate2− (intracellular) + Formate− (extracellular)	Electrochemical gradients; electrogenic 1:1 antiport contributing to Δψ	[5]
Activation	Formyl-CoA transferase (Frc)	Oxalate + Formyl-CoA	Oxalyl-CoA + Formate	CoA-transferase; ping-pong bi-bi mechanism (enzyme-bound thioester intermediate)	[4,37]
Decarboxylation	Oxalyl-CoA decarboxylase (Oxc)	Oxalyl-CoA	Formyl-CoA + CO2	Thiamine diphosphate (ThDP/TPP), Mg2+; proton consumption contributes to ΔpH	[44]
Recycling (Optional)	Formate dehydrogenase (FDH; strain-dependent)	Formate + NAD+	CO2 + NADH + H+	NAD+	[43]
Energy Coupling	F0F1-ATP synthase (Complex V)	ADP + Pi + H+ (periplasm/extracellular)	ATP + H2O + H+ (cytoplasmic)	Proton motive force (PMF = Δψ + ΔpH)	[4,37]

Note: This table summarizes the main biochemical reactions, enzymes, substrates, products, and cofactors, on the basis of recent studies of the anaerobic pathway in such bacteria as O. formigenes and environmental isolates. This mechanism supports oxalate turnover and bacterial energy conservation through proton motive force generation.

).

One of the key characteristics of this pathway is that it is tightly linked to membrane energetics. OxlT is an electrogenic oxalate 2-/formate-antiporter, and this charge gradient can be used to produce proton-motive-force, which can be used to generate ATP [5]. Consequently, to achieve efficient oxalate degradation in vivo, not only are the frc and oxc genes required, but so are the efficiency of transport, formate efflux, and a favorable pH gradient across the cell membrane [45]. This energetic dependence may help explain why some bacteria carrying the pathway fail to show meaningful oxalate-degrading activity in the intestinal environment.

2.2. Mechanism of Frc: Activation of Oxalate to Oxalyl-CoA

A formyl-CoA transferase, Frc, is the enzyme that starts the core pathway of oxalate degradation by transferring CoA to activated oxalate to generate oxalyl-CoA [46]. This is a critical step because it activates oxalate for decarboxylation and is a suggested rate-limiting step of the pathway [44]. Structural studies reveal that Frc is highly conserved and that residues in the active site play a critical role in CoA transfer and transition-state stabilization [47]. A thiamine pyrophosphate-dependent enzyme, Oxc, catalyzes the oxalyl-CoA decarboxylation process to formyl-CoA and CO₂. This reaction restores the CoA donor needed to proceed with Frc activity, and promotes cyclic pathway activity [48]. Oxc requires cofactors (thiamine pyrophosphate and Mg²⁺) for activity and typically works under slightly acidic environments, which are found in certain gut microenvironments [48]. Metagenomic surveys suggest that oxc homologs are commonly found in oxalate-rich environments [44], whereas probiotic strains show significant oxalate reduction mediated by Oxc, which is controlled by pH and growth conditions [36]. Together, Frc and Oxc form a tightly linked metabolic unit that enables efficient oxalate utilization under anaerobic conditions in the gut.

From a therapeutic perspective, Frc and Oxc are crucial not only due to their enzymatic roles but also because they are coupled with the OxlT-dependent transport and PMF production (Figure 1) [40]. OxlT-based oxalate/formate exchange also plays a role in the production of proton-motive-force, connecting oxalate degradation to bacterial energy conservation [5,44]. In other words, the activity of the Frc–Oxc pathway in vivo relies on the presence of a functional system and not just the abundance of enzymes [40]. This is especially relevant when considering probiotic applications, because strains that contain frc and oxc may still be useless if the intestinal environment of the body does not support transport energetics or pathway induction.

2.3. Comparison with Alternative Oxalate Degrading Pathways (ODPs)

ODPs are a broad category covering all biological mechanisms that break down oxalate [10]. The OCP is a subset of ODPs that precisely involves only CoA-dependent routes [49]. The Frc–Oxc pathway differs from alternative oxalate degradation schemes in apparatus, oxygen requirement and energetic yield [39,40]. Some fungal and aerobic bacterial OxDCs can directly convert oxalate to formate and CO₂ but involve oxygen and manganese, making them inappropriate for anaerobic gut environments (Figure 2(1)) [50]. Plant oxalate oxidase generates H₂O_2, which functions primarily in defense rather than energy uptake (Figure 2(3)) [51]. Type V oxdC pathways in bacteria also decarboxylate oxalate, although they do not provide the energy-coupled transport advantage provided by OxlT [40]. Aerobic integration pathways not only use glyoxylate and hydroxypyruvate as intermediates to enter central metabolism but also show inconsistent activity due to strain-specific polymorphisms (Figure 2(4)) [49]. The Frc–Oxc pathway is very effective at degrading insoluble oxalates, and it allows biomineralization, which has been used to detoxify metal oxalates (e.g., lead oxalate to phosgenite) (Figure 2(2)) [52]. Its strict anaerobic efficiency also makes it a capable therapeutic target for probiotic development [12]. Collectively, these biochemical steps highlight that Frc–Oxc oxalotrophy is inseparable from OxlT-mediated oxalate/formate exchange and PMF generation.

3. Structural and Functional Characteristics of Frc and Oxc

3.1. Crystal Structures and Active Sites of Frc

Structural analyses show that Frc is a homodimer, and each monomer cooperates in a shared CoA-binding site, which is crucial for the formation of oxalyl-CoA [46,47]. Residues (Q17, W48, D169 and G259-G260) are highly conserved among different groups of organisms and participate in transition state stabilization and prevent unproductive hydrolysis [47,53,54]. The dimeric architecture forms a narrow access channel and a flexible substrate entrance that protect intermediates [47]. Mutant studies show that changes in residues like G259 may inhibit dimer formation and the enzyme’s activity [53]. Environmental adaptation in extremophiles, such as modified surface properties, may help to increase enzyme stability under high salt conditions [55]. These features make Frc a promising candidate for engineering strains with enhanced oxalate-degrading capacity [47]. Structural studies indicate that Frc should be viewed not only as a simple CoA-transfer enzyme but also as a conserved catalytic platform that controls the entry of oxalate into the energy-linked degradation cycle. The crystal structure of O. formigenes formyl-CoA transferase revealed an interlocked homodimeric architecture, with the CoA-binding site positioned within a protected structural environment that supports efficient substrate handling [47]. Kinetic and mechanistic studies further confirmed that Frc catalyzes CoA transfer from formyl-CoA to oxalate, producing oxalyl-CoA as the activated intermediate required for downstream Oxc activity [46]. Therefore, disruption of dimer stability, CoA binding, or active-site organization could reduce pathway flux even when the frc gene is present.

3.2. TPP-Dependent Catalysis of Oxc

Oxc is a thiamine pyrophosphate (TPP)-dependent enzyme with quaternary structures ranging from dimers in eukaryotes to tetramers in bacteria, and stabilized under anaerobic conditions [56]. The active site lies within a cleft, with TPP bound to pyrimidine-binding (PYR) and pyrophosphate-binding (PP) domains with Mg₂₊ and highly conserved residues (E56, Y120, E121 and R555) [48,57]. The enzyme catalyzes non-oxidative decarboxylation by forming a covalent bond between TPP and oxalyl-CoA. Adenosine diphosphate (ADP) positively allosterically activates the reaction by binding to regulatory pocket residues, thereby significantly increasing the substrate turnover rate [57]. The enzyme’s optimal pH of 5.5–6.0 is adapted to low pH environments of the gut and soils [56]. Engineered Oxc variants have been explored for synthetic one-carbon metabolism and carboligase applications [15]. TPP-binding residues are conserved among microorganisms to maintain enzyme activity [56]. The Oxc reaction provides the biochemical driving force that maintains the cyclic Frc–Oxc pathway. Oxc is a thiamine diphosphate-dependent decarboxylase that converts oxalyl-CoA to formyl-CoA and CO₂, thereby regenerating the formyl-CoA donor required for the Frc reaction [57]. Structural analysis of Oxc from O. formigenes showed that cofactor binding, Mg²⁺ coordination, and activation by ADP are important for catalytic function [57]. Thus, Oxc activity is influenced not only by the presence of oxc but also by cofactor availability, protein assembly, pH, and metabolic state.

3.3. Gene Organization and Operon Architecture

In many oxalotrophic bacteria, frc and oxc and sometimes oxlT genes are organized as a small operon, allowing for co-regulation and rapid response to oxalate presence [56,58]. Genomic analyses reveal widespread presence of the operon in Proteobacteria, Actinobacteria and Firmicutes, suggesting horizontal gene transfer in various environments [12,59]. The frc and oxc genes are separated by a short intergenic sequence, which is mostly less than 100 bp and enables a bicistronic transcript. Operon promoters are pH-sensitive with increased activity, facilitating transcription in the acidic conditions of oxalate-enriched habitats [60,61]. Research on co-expression suggests that the structure of an operon may improve its degradation capacity and make it a helpful approach for engineered microbial systems [15]. The organization of oxlT, frc, and oxc is functionally important because oxalate uptake, CoA transfer, decarboxylation, and formate export must operate as a coordinated module. OxlT mediates oxalate/formate exchange, while Frc and Oxc convert imported oxalate into formate and CO₂, allowing the pathway to function as an integrated transport–metabolism system [40,42]. When these genes are physically linked or co-regulated, bacteria can more efficiently activate the complete oxalate-degradation pathway in response to oxalate availability. In contrast, fragmented organization or weak regulatory coupling may result in incomplete pathway activity despite the presence of individual pathway genes [14,39].

3.4. Regulation of Enzyme Expression

The frc and oxc genes are generally induced by oxalate and regulated by pH, with optimal expression at low pH levels [12,60]. Oxalate likely acts as a co-inducer, binding to regulatory proteins or sensor-kinase complexes regulating transcription of the operon [42,62,63]. Carbon availability also affects expression, with glucose being able to inhibit the operon in some strains [36,44]. Environmental isolates demonstrate time-dependent induction, with the highest transcript abundance occurring after prolonged exposure to oxalate [42,45,64]. The proteomics information shows that Frc and Oxc are more abundant under oxalate exposure, while high pH suppresses the operon and prevents deleterious side effects [42,44]. This ON/OFF regulatory strategy reflects adaptation to a wide range of environmental habitats [10,65]. A common oversight of probiotic studies is that frc–oxc is not always on; it is a highly regulated stress-response/energy-salvage operon. For many facultative degraders, the operon is turned on only under low-carbon, mildly acidic and oxalate-rich environments. High-carbon diets (glucose or fat) can invoke catabolite repression and turn off gene transcription, allowing these bacteria to ferment more favored substrates [66]. Therefore, the same probiotic strain may degrade oxalate robustly in vitro but not in the human host with a diet rich in other carbon. This regulatory logic has direct clinical relevance, predicting that probiotic efficacy is highly niche-dependent and remains mechanistically incomplete without concurrent management of substrate, diet, and local pH [25]. In O. formigenes, oxalate metabolism is linked to proton-motive-force generation, and external pH influences the electrical and chemical components of the proton gradient during oxalate metabolism [67,68]. In lactobacilli, oxc and frc homologs can be transcriptionally and functionally associated with oxalate degradation, but activity varies with strain and culture conditions [42]. Consequently, a bacterium may show strong oxalate degradation under controlled in vitro conditions but weaker activity in vivo, where oxalate availability, pH, bile acids, antibiotics, and microbial competition vary among individuals [36]. The inducible, catabolite-gated nature of frc–oxc operon (summarized in Figure 3) provides a mechanistic explanation for why oxalate-degradation genes frequently fail to translate into in vivo activity.

3.5. Structure-Function Analysis of Mutants and Recombinant Enzymes

Catalytic insights into Frc and Oxc have been revealed by mutant and recombinant approaches [47,48]. oxc and frc knockout mutants lose the ability to degrade oxalate [42]. Coenzyme-binding site mutations in Oxc (e.g., E121Q, S568A, Y497A) impact the binding or rates of TPP turnover, although directed evolution has improved the catalysis for artificial purposes [48,69]. Studies of fungus-growing termite nests have linked oxalate-degrading bacterial communities with environmental oxalate–carbonate transformation [70]. Together, these functional studies highlight the adaptability and potential uses for Frc–Oxc [36]. The structural basis for Frc/Oxc performance and inducible operon regulation shows that oxalate degradation is permissive and easily shut down by carbon sufficiency and non-permissive pH. These regulatory constraints refine the ONI model and directly imply that responder status depends on niche permissiveness as much as on gene carriage. Mutant, recombinant, and structure–function studies collectively show that the Frc–Oxc pathway is modular but not automatically functional. OxlT structure–function studies demonstrated that membrane topology and transporter residues are important for oxalate/formate exchange [5,71], while Frc and Oxc structural studies showed that active-site integrity and cofactor-dependent catalysis are essential for pathway flux [47,57]. Functional studies in lactobacilli further show that the presence of frc and oxc homologs must be supported by measurable oxalate-degrading activity [42]. Therefore, future strain screening should combine genomic detection with enzyme activity assays, oxalate-degradation measurements, transport-function assessment, and colonization-performance studies.

4. Evolution and Distribution of frc and oxc Genes

4.1. Phylogenetic Distribution and Functional Diversity

The frc and oxc genes are distributed across diverse bacterial lineages, indicating that microbial oxalate metabolism is not restricted to O. formigenes [13,72]. Among these organisms, O. formigenes remains the best-characterized intestinal oxalotroph and uses the OxlT–Frc–Oxc system for anaerobic oxalate transport, CoA transfer, decarboxylation, formate production, and transport-linked energy conservation [73]. Comparative OXC analyses further show that oxalyl-CoA decarboxylase homologs occur across several bacterial groups, including Proteobacteria, Actinobacteria, Firmicutes/lactobacilli-associated taxa, Bacteroidetes-related taxa, and other environmental or host-associated bacteria [72]. This broad distribution suggests that oxalate-degrading capacity may contribute to different ecological functions, including oxalate detoxification, intestinal oxalate turnover, carbon cycling, pH modulation, and environmental oxalate transformation [13,72,73]. In host-associated systems, oxalate-degrading bacteria have been reported in human and animal gut microbiomes, where their abundance and activity may influence luminal oxalate availability and urinary oxalate burden [11,74,75].

However, oxalate-degrading potential should not be inferred from taxonomy alone. Some lactobacilli, bifidobacteria, enterococci, and other gut-associated bacteria show strain-dependent oxalate-degrading activity, but functional validation is required because gene presence does not necessarily prove active oxalate degradation in vivo [75,76]. Because the former broad genus Lactobacillus was taxonomically reorganized in 2020, this review uses the lowercase, non-italicized term “lactobacilli” when referring broadly to organisms historically grouped within Lactobacillaceae [77]. Where species identity is clear, updated genus names should be used; where older studies used pre-2020 nomenclature, the original name is retained only to remain consistent with the cited literature. Therefore, candidate probiotic strains should be evaluated using genomic screening together with frc/oxc expression, enzyme activity, oxalate-degradation assays, transport function, and colonization performance.

4.2. Identification of Oxc Homolog Clusters

Comparative analyses of oxalyl-CoA decarboxylase (OXC/oxc) homologs show that this enzyme family is taxonomically diverse and is not restricted to O. formigenes. Jiang et al. classified 1396 putative OXC sequences into seven major clusters based on sequence similarity, taxonomic distribution, gene-context organization, and human microbiome body-site abundance [72]. This cluster framework provides a useful baseline for mapping OXC diversity within human microbiome datasets, although it should be interpreted primarily as a bioinformatic classification rather than direct evidence that every recovered homolog is functionally active in vivo. Cluster 1 includes the experimentally characterized OXC from O. formigenes, an obligate anaerobic gut bacterium that relies strongly on oxalate metabolism for growth and transport-linked energy conservation [72,73]. Cluster 2 contains the E. coli OXC homolog and related Gammaproteobacteria-associated sequences; in E. coli, YfdU/OXC and YfdW/Frc are required for oxalate-induced acid tolerance, indicating that some OXC homologs may contribute to acid-resistance physiology as well as oxalate metabolism [62]. Clusters 3 and 5 are mainly associated with Actinobacteria, including Mycobacterium- and Bifidobacterium-related representatives, whereas Cluster 4 contains Bacilli-associated homologs, including lactobacilli-associated OXC sequences [72]. Functional studies support the biological relevance of several non-Oxalobacter OXC-containing bacteria. In lactobacilli, frc and oxc homologs have been transcriptionally and functionally associated with oxalate degradation, although activity is strain-dependent [42,78]. In bifidobacteria, OXC/oxc has been molecularly characterized in Bifidobacterium lactis, and oxalate-degrading activity has been reported in Bifidobacterium animalis subsp. lactis, including under acidic conditions [79,80]. These findings demonstrate that OXC homologs occur across probiotic-associated bacterial groups, but functional activity should be experimentally validated rather than inferred only from broad taxonomic assignments.

Table 2. Literature-supported summary of representative oxalyl-CoA decarboxylase (OXC/oxc) clusters and reported ecological distribution.

Cluster	Representative Organism/Sequence	Main Taxonomic Association Reported	Reported Ecological or Microbiome Distribution	Evolutionary Interpretation	Citation
1	Oxalobacter formigenes OXC, P40149	Diverse bacterial classes, including Alpha-, Beta-, and Gammaproteobacteria	Relatively high in gut datasets; also detected across human microbiome body sites	dN/dS < 1, consistent with purifying selection	[72]
2	Escherichia coli OXC, P0AFI0/P0AFI1	Mainly Gammaproteobacteria	Relatively low in gut but enriched in vaginal-site datasets	dN/dS < 1, consistent with purifying selection	[72]
3	Mycobacterium intracellulare OXC, H8IJH4	Actinobacteria	Detected in human microbiome datasets; relatively enriched in vaginal-site datasets compared with gut	dN/dS < 1, consistent with purifying selection	[72]
4	Lactobacillus acidophilus OXC, A0A378H7I7	Bacilli / Firmicutes	Relatively enriched in vaginal-site datasets; includes LAB-associated OXC homologs	dN/dS < 1, consistent with purifying selection	[72]
5	Bifidobacterium animalis OXC, B8DWU2	Actinobacteria	Detected in human microbiome datasets; includes bifidobacterial OXC homologs	dN/dS < 1, consistent with purifying selection	[72]
6	Porphyromonadaceae bacterium OXC, A0A3B8R5P5	Bacteroidia-associated representative sequence	Low abundance in the HMP body-site abundance analysis	dN/dS < 1, consistent with purifying selection	[72]
7	Acetobacter sp. BCRC 14118 OXC, A0A368AD84	Alphaproteobacteria	Not detected in the HMP body-site abundance analysis reported by Jiang et al.	dN/dS < 1, consistent with purifying selection	[72]

Note: This table summarizes the seven taxonomic clusters and human microbiome body-site distribution of oxalyl-CoA decarboxylase (OXC/oxc) homologs reported by Jiang et al. [72]. Cluster 1 was relatively high in gut datasets, whereas Clusters 2–4 were relatively enriched in vaginal-site datasets. The distribution of these homologs indicates that oxalate-degrading potential extends beyond the classical obligate oxalotroph O. formigenes and occurs across diverse human microbiome-associated bacterial groups.

summarizes the seven OXC clusters according to representative taxa, dominant taxonomic associations, reported microbiome distribution, and evolutionary interpretation. Overall, OXC cluster assignment should be combined with frc/oxc co-occurrence, gene-expression evidence, enzyme assays, oxalate-degradation measurements, and ecological context when evaluating candidate probiotic strains for kidney stone prevention.

4.3. Evolutionary Conservation and Selection Pressures

Evolutionary analyses indicate that frc and oxc are generally conserved across oxalate-degrading microbial lineages, particularly in regions associated with catalysis, substrate binding, and cofactor-dependent function [72]. This conservation suggests that oxalate metabolism provides a selective advantage in microbial niches where oxalate is available as a carbon or energy-related substrate [13,73]. The strong purifying selection on key residues in specialized OxB reflects the Frc–Oxc pathway’s essential role for growth and survival under oxalate-rich environments. Figure 4 further illustrates the broad distribution and taxonomic structuring of OXC homologs across several bacterial clusters based on reanalysis of the Jiang et al. supplementary dataset [72]. The conservation of these genes also has practical significance. It indicates that the enzymatic core of the Frc–Oxc pathway is stable across different taxa [73], which may help in identifying candidate probiotic strains or predicting oxalate-degrading potential from genomic data. At the same time, conserved sequence alone should not be interpreted as proof of an effective in vivo function because pathway activity remains dependent on regulation, transport coupling, and ecological context.

4.4. Horizontal Gene Transfer Events

Phylogenetically diverse bacteria that contain frc and oxc suggest that horizontal gene transfer (HGT) may have contributed to the spread of oxalate-degrading capacity [41,72]. The inter-lineage transfer of highly conserved, operon-like gene arrangements may have enabled distinct taxa across contrasting ecological niches to rapidly acquire specialized oxalate-associated metabolic functions [64]. This evolutionary mechanism explains the widespread presence of homologous pathway components in organisms possessing vastly different metabolic strategies and lifestyles [74,81]. From a translational perspective, the occurrence of these historical HGT events indicates that functional oxalate-degrading traits are distributed across a diverse range of gut-associated taxa rather than being restricted to a single specialized organism [82,83]. In summary, horizontal gene transfer may have shaped the genetic diversity and ecological distribution of the oxalate-degrading genes within the human microbiome [13,15]. These evolutionary insights support the paradigm that host oxalate homeostasis is mediated by a multi-taxonomic spectrum of organisms, suggesting that clinical strategies targeting hyperoxaluria must adopt a community-level, ecosystem-based approach to successfully restore metabolic function.

4.5. Prevalence in Human Microbiomes

Large-scale metagenomic studies show that frc and oxc are widely distributed in the human gut microbiome, indicating that oxalate degradation is a common functional trait [10,80,84]. A study of 660 healthy subjects found that oxc was detected in approximately 84% of individuals, while frc was detected in approximately 88%. These genes were predominantly associated with Cluster 1 O. formigenes [10]. In contrast, complete oxalotrophy is a relatively rare metabolic trait, largely confined to the gut, with limited occurrence in oral and respiratory microbiomes [13,41,85]. Dysbiosis in kidney stone patients is associated with reduced oxc prevalence, potentially contributing to elevated urinary oxalate excretion and increased stone risk [85,86]. The prevalence varies with age and diet, with higher abundance observed in adults compared to neonates, and in populations consuming oxalate-rich diets [2,12]. In inflammatory bowel disease (IBD), reduction of oxalate degraders further exacerbates hyperoxaluria [10]. These patterns highlight the pathway’s clinical relevance and support interventions aimed at restoring the oxalotrophic taxonomic group in dysbiotic communities [85,87]. Overall, the evolutionary distribution of frc and oxc supports the central importance of the Frc–Oxc pathway in microbial oxalate metabolism. At the same time, phylogenetic breadth and genomic conservation do not eliminate the need to consider pathway regulation and ecological context when evaluating therapeutic potential in human calculi.

5. Environmental Factors Influencing Oxalate Degradation

5.1. Impact of pH and Carbon Sources

Environmental pH is an important regulator of microbial oxalate degradation, but its effect differs between specialist and facultative oxalate degraders. In the obligate oxalotroph O. formigenes, optimal oxalate degradation and growth are generally reported under mildly acidic to near-neutral conditions, approximately pH 6.0–7.0, whereas stronger acidity, such as pH 4.5, can substantially reduce transcriptional activity and degradation efficiency [13,88,89]. In contrast, some lactic acid bacteria (LAB) and Bifidobacterium strains may use frc–oxc-associated oxalate degradation as part of an acid-stress adaptation response, where subinhibitory acidic conditions can stimulate operon expression and improve oxalate-degrading activity [88,90]. Therefore, the pH requirement for oxalate degradation should be interpreted as strain- and niche-dependent rather than universal across all oxalate-degrading bacteria.

Carbon availability further modulates oxalate-degrading activity through distinct ecological mechanisms. In facultative oxalate degraders, easily fermentable carbohydrates such as glucose and sucrose may enhance biomass formation and indirectly support enzyme production [36,78]. Under carbon-limited conditions, some generalist degraders may increase reliance on alternative substrates and induce oxc transcription to utilize oxalate [47,56,91]. However, excess preferred carbon sources may reduce oxalate-pathway activity through metabolic regulation or carbon catabolite repression mechanisms [64,92]. Prebiotics may also influence oxalate degradation by supporting bacterial growth, modifying gut niche conditions, or improving substrate availability; for example, inulin-containing formulations have been reported to enhance degradation performance in selected kinetic or optimization assays [4,9,45]. However, these effects should be considered formulation- and strain-specific rather than generalizable to all oxalate-degrading bacteria.

In the gut, these factors have practical therapeutic implications. Local pH gradients, substrate availability, and competing nutrients can determine whether the Frc–Oxc pathway is active or functionally silent [28,93,94]. Thus, probiotic efficacy depends not only on bacterial administration but also on whether the intestinal environment supports pathway induction and transport-linked oxalate metabolism.

Table 3. Reported culture- and host-regulated factors influencing microbial oxalate degradation.

Factor	Reported Condition/Factor	Organism/System	Reported Effect	Citation
pH	pH 5.5	Lactobacillus acidophilus ATCC 4356	Reported as a favorable condition for oxalate degradation in optimized in vitro assays	[95]
Glucose	37.46 g/L	L. acidophilus ATCC 4356	Included among optimized process variables for oxalate degradation	[95]
Inulin	0.987 g/L	L. acidophilus ATCC 4356	Included among optimized process variables supporting oxalate degradation	[95]
Sodium oxalate	~22.8 mmol/L	L. acidophilus ATCC 4356	Used as optimized substrate condition in in vitro oxalate-degradation assay	[95]
pH	pH 6.0	O. formigenes DSM 4420	Final optimized condition for ammonium oxalate biodegradation	[96]
Glucose	36.56 g/L	O. formigenes DSM 4420	Final optimized medium component; model estimated oxalate biodegradation of ~60.2%	[96]
Inulin	1.35 g/L	O. formigenes DSM 4420	Final optimized prebiotic condition for ammonium oxalate biodegradation	[96]
Ammonium oxalate	26 mmol/L	O. formigenes DSM 4420	Final optimized substrate condition; ammonium oxalate decreased to about 9.95 mmol/L	[96]
Temperature/culture condition	Laboratory culture conditions (30 °C, 180 rpm)	Azospirillum sp. OX-1	Calcium oxalate degradation with Frc/Oxc involvement reported	[44]
Bile acids	Altered bile acid metabolism	Gut microbiota/CaOx model	Host–microbiome modulatory factor	[97]

Note: The listed values are derived from different experimental systems, strains, substrates, and assay conditions; therefore, they should not be directly compared across organisms. For studies using response-surface or optimization models, the values represent reported optimized or influential in vitro variables rather than universal physiological optima. Overall, microbial oxalate degradation is not controlled by a single optimum condition, but depends on strain-specific culture requirements and host-related ecological factors that together determine pathway activity.

summarizes the ideal conditions for representative taxa.

5.2. Role of Prebiotics and Nutritional Supplements

Prebiotics significantly enhance intestinal oxalate degradation by providing fermentable substrates that drive the proliferation and metabolic activity of oxalate-consuming bacterial cohorts [36]. Non-digestible oligosaccharides, such as inulin and fructooligosaccharides (FOS), have been reported to increase the oxalate-degrading activity of certain probiotic strains by approximately 38%, while altered gut microbiota is associated with renal stone risk [76,98]. This metabolic enhancement is driven primarily by biomass expansion, improved mucosal colonization, and the production of short-chain fatty acids that lower local pH, which indirectly facilitates the upregulation of frc–oxc operon expression [42]. Notably, in vivo models of hyperoxaluria have demonstrated that prebiotic administration successfully reduces urinary oxalate excretion [99].

Synbiotic strategies leverage these dynamics by co-administering synergistic probiotic strains alongside specific prebiotic substrates, thereby maximizing bacterial survival, metabolic transit, and functional consistency within the competitive gastrointestinal tract [100,101]. Beyond luminal degradation, certain systemic nutritional adjuncts can target endogenous pathways. For instance, vitamin B6 serves as an essential cofactor for hepatic alanine-glyoxylate aminotransferase (AGT); its supplementation prevents the metabolic shunting of glyoxylate toward endogenous oxalate production [4,12,102]. Although these findings are encouraging, the main value of prebiotics in this context is that they may help create a more supportive environment for pathway activity rather than serving as stand-alone therapies [74,103]. This makes them especially relevant for improving the consistency of microbiome-based interventions targeting hyperoxaluria and calcium oxalate stone risk.

5.3. Effects of Antibiotics and Microbial Disruptions

Antibiotic administration can impair intestinal oxalate degradation by disrupting oxalate-degrading microbial communities, particularly O. formigenes. Population-based studies have reported an association between oral antibiotic exposure and increased odds of nephrolithiasis, with stronger associations after recent exposure and in younger individuals [20,104,105]. This relationship is biologically plausible because antibiotics can reduce colonization by oxalotrophic bacteria and disturb microbiome functions involved in oxalate handling. Broad-spectrum antibiotic classes, including fluoroquinolones, cephalosporins, sulfonamides, nitrofurantoin, and broad-spectrum penicillins, have been associated with increased kidney stone risk in epidemiological analyses [106,107,108]. Microbial disruption may be especially relevant in inflammatory bowel disease (IBD) and other dysbiotic gut conditions. Multi-omics studies indicate that oxalate-degrading gene expression, including frc and oxc transcripts, can be reduced in IBD-associated microbiomes, even when oxalate-degradation genes are still detectable [10,43].

Repeated or prolonged exposure to antimicrobial agents can persistently alter gut microbiome structure. This selective pressure may reduce the community-level capacity to degrade metabolic compounds while favoring resistant microbial populations that may lack beneficial oxalate-degrading functions [86,109]. Human strains of O. formigenes exhibit sensitivity to several widely prescribed outpatient antibiotic classes, including macrolides, fluoroquinolones, clindamycin, tetracyclines, aminoglycosides, and metronidazole [105]. This susceptibility profile provides a mechanistic explanation for why antibiotic exposure can compromise colonization stability and decrease functional oxalate degradation, even when oxalate-degrading genes remain detectable by metagenomic analysis. Ultimately, these dynamics underscore the importance of antibiotic stewardship and highlight the need for targeted adjuvant strategies designed to conserve, restore, or protect native oxalotrophic populations during clinical interventions [12,74,82].

5.4. Influence of Host Diet and Oxalate Load

Host diet is an important driver shaping the composition and metabolic activity of the oxalate-degrading gut microbiota [2]. Diets rich in oxalate may increase the abundance or activity of frc/oxc-positive taxa and enhance luminal oxalate-degrading capacity, whereas prolonged restriction of dietary oxalate may reduce substrate availability for specialized oxalotrophs [15,73]. At the molecular level, elevated oxalate availability can induce oxc expression in O. formigenes, while dietary fibers and prebiotic substrates may support the growth of selected facultative oxalate-degrading bacteria, including some LAB [11,36,76]. Animal studies further suggest that oxalate-rich diets, including spinach-supplemented regimens, can modify intestinal oxalate-degrading activity, whereas high-fat-diet-associated dysbiosis may suppress native oxalotrophic populations and promote intestinal oxalate absorption [2,89,110]. Human dietary and clinical studies also indicate that diet-dependent changes in gut microbial function and oxalate availability can influence urinary oxalate excretion and nephrolithiasis risk, supporting the therapeutic potential of targeted nutritional modulation [12,14,61,111].

These dietary dynamics are important because urinary oxalate excretion depends strongly on gastrointestinal solubility and absorption kinetics, not on oxalate intake alone. Co-ingested dietary calcium can bind free oxalate in the intestinal lumen to form poorly soluble calcium oxalate complexes, thereby reducing the bioavailable pool of soluble oxalate [18,23]. Conversely, low dietary calcium intake, high soluble oxalate intake, fat malabsorption, and altered intestinal transit can increase soluble oxalate absorption and subsequent urinary oxalate excretion [18,112]. Therefore, diet can influence Frc–Oxc-based therapy in two opposite ways: sufficient oxalate may be needed to induce microbial oxalate-degradation pathways, but excessive soluble oxalate absorption can increase urinary stone risk if microbial degradation or mineral binding is insufficient.

5.5. In Vitro and In Vivo Modulation Strategies

Experimental studies show that oxalate degradation can be improved in vitro through optimization of pH, substrate conditions and prebiotic supplementation [28,86]. These in vitro systems are useful for identifying favorable growth and degradation conditions, but their results should be interpreted as strain- and assay-specific rather than directly transferable to the human gut [95,96]. Multi-strain probiotic and synbiotic approaches have also been tested in oxalate-degradation contexts, where responses appear to depend on strain compatibility, formulation design, and environmental conditions [12,76,86]. In vivo strategies aim to move beyond culture optimization by restoring or enhancing oxalate-degrading function within the host intestinal ecosystem. Probiotic and synbiotic administration, fecal microbiota transplantation, and engineered live biotherapeutic products have all been investigated as approaches to increase host oxalate-degrading capacity [13,113,114]. However, successful in vivo activity requires more than the presence of an administered organism; the intestinal niche must also support colonization, pathway induction, and sustained oxalate metabolism [11,74].

Local pH, carbon co-substrates, oxalate availability, and prebiotic support are key culture-related axes of “oxalate-niche permissiveness”. Host bile acid profiles and antibiotic history further modify this niche by altering gut microbiome structure and oxalotrophic stability [96,97]. Together, these factors may determine whether the frc–oxc pathway is induced, weakly active, or functionally inactive, thereby influencing whether administered strains can colonize, persist, and produce measurable oxalate-lowering effects [74]. Recent in vivo validation studies support this niche-based interpretation. In a high-oxalate diet model, fecal microbiota transplantation (FMT) reduced urinary oxalate excretion and renal calcium oxalate crystal deposition while restoring gut microbial and metabolomic profiles [114]. Similarly, induced O. formigenes colonization in healthy adults reduced urinary oxalate excretion, although persistence and response varied among individuals [74]. Baseline abundance of oxalate-degrading bacteria and frc/oxc genes has also been linked to variation in response to O. formigenes administration [11]. These findings support a therapeutic framework in which effective oxalate reduction depends on colonization stability, dietary compatibility, and a permissive host intestinal environment, rather than the mere presence of an oxalate-degrading organism.

6. Probiotic and Microbiome-Based Therapeutic Applications

6.1. Oxalate-Degrading Bacteria of Therapeutic Interest

Oxalate-degrading biotherapies aim to reduce the soluble intestinal oxalate pool before absorption and thereby lower urinary oxalate burden [25,113]. Among these organisms, O. formigenes remains the most specialized gut oxalotroph; it uses oxalate as a major metabolic substrate and relies on the coordinated OxlT–Frc–Oxc system for oxalate transport, CoA transfer, decarboxylation, formate production, and transport-linked energy conservation [73,74]. This metabolic specialization makes O. formigenes an important candidate for oxalate-targeted biotherapy, although its clinical performance depends on colonization stability, substrate availability, antibiotic exposure, and host intestinal ecology [74,105]. Therefore, delivery strategies for O. formigenes should prioritize preservation of viability, protection from oxygen and gastrointestinal stress, and support for intestinal engraftment [104,115]. Alternative candidate probiotics include strains of lactobacilli, bifidobacteria, and enterococci, which show distinct, strain-dependent oxalate-degrading phenotypes [76].

However, functional oxalate degradation cannot be inferred from genus-level identity alone. The term “lactobacilli” is used here when referring broadly to organisms historically grouped within Lactobacillaceae, following the major 2020 taxonomic reorganization of the former broad genus Lactobacillus [77]. These facultative degraders remain clinically attractive because many strains have established probiotic use, acid-stress tolerance, and compatibility with commercial probiotic manufacturing pipelines [25,76]. Multi-strain consortia may offer advantages over single-strain interventions by combining complementary oxalate-degrading and niche-supporting functions [76]. However, consortium efficacy remains formulation- and host-dependent and should be validated using functional oxalate-degradation assays rather than inferred from strain lists alone [76]. Beyond wild-type isolates, genetically engineered live biotherapeutic products represent an additional therapeutic avenue [113]. Engineered platforms may be designed to enhance gastrointestinal oxalate consumption and improve predictable oxalate-lowering activity, but they require rigorous evaluation of safety, stability, containment, and long-term clinical efficacy before use in calcium oxalate nephrolithiasis prevention [113].

6.2. Preclinical Evidence: In Vitro, Animal, and Engineered-Strain Studies

Preclinical investigations provide foundational evidence for oxalate-targeted microbial therapeutics. In vitro optimization models demonstrate that microbial oxalate degradation depends on environmental pH, substrate availability, nutrient composition, and prebiotic supplementation, although these responses remain strain- and assay-specific [76,96,113]. These systems are useful for identifying favorable metabolic conditions, but static in vitro cultures cannot fully reproduce the complex physiology of the host gastrointestinal tract, including regional pH gradients, bile acid exposure, microbial competition, and host-specific colonization barriers [73,97].

To bridge this translational gap, animal models and engineered live biotherapeutic products provide functional evidence for whether microbial oxalate degradation can alter host oxalate handling. Synthetic biology has emerged as a promising strategy to improve the predictability and robustness of oxalate-degrading activity. A prominent example is SYNB8802, an engineered Escherichia coli Nissle 1917 strain designed to consume oxalate in the gastrointestinal tract [113,116]. In preclinical studies, oral SYNB8802 significantly reduced urinary oxalate excretion in healthy mice and non-human primates, and in silico modeling predicted potential urinary oxalate lowering in humans with enteric hyperoxaluria [113,117]. Similarly, Whitaker et al. developed NB1000S, an engineered porphyran-utilizing Phocaeicola vulgatus strain carrying an oxalate-degradation pathway and a conditional attenuation system for controlled gut colonization. In a dietary enteric-hyperoxaluria rat model, the engineered strain reduced urinary oxalate by 47% compared with a control strain lacking the oxalate-degradation pathway, while the human phase 1/2a study showed controlled colonization but also highlighted genetic stability and long-term treatment-control challenges [118]. These engineered platforms may help overcome some limitations of native obligate oxalotrophs, including strict colonization requirements and variable persistence. However, translating preclinical success into human therapy requires rigorous evaluation of long-term biosafety, dose–response behavior, ecological stability within the native microbiome, biocontainment strategies, and sustained oxalate-lowering efficacy in vivo [113,119].

6.3. Human Clinical Evidence and Variable Outcomes

Human clinical evidence for oxalate-targeted microbial interventions remains mixed and is characterized by notable inter-individual variability. Early studies using mixed lactic acid bacterial preparations, such as Oxadrop^®, reported reductions in urinary oxalate excretion in small cohorts of patients with enteric hyperoxaluria [7,30,120]. However, a later randomized, double-blind, placebo-controlled trial of Oxadrop^® in calcium stone formers with idiopathic hyperoxaluria did not show a significant reduction in urinary oxalate compared with placebo [121]. These findings indicate that conventional microbial supplementation alone is insufficient to guarantee reproducible oxalate-lowering efficacy. Clinical trials using native O. formigenes have also produced variable outcomes. In primary hyperoxaluria, orally administered O. formigenes was generally well tolerated, but larger randomized trials did not consistently show significant urinary oxalate reduction compared with placebo. This limitation is biologically plausible because primary hyperoxaluria is mainly driven by hepatic oxalate overproduction, which may exceed the capacity of localized intestinal microbial degradation [111,122,123].

In contrast, gut-directed microbial therapies may be more mechanistically relevant in enteric or idiopathic hyperoxaluria, where intestinal oxalate absorption and luminal oxalate bioavailability contribute directly to urinary oxalate burden [23,120]. In idiopathic calcium oxalate nephrolithiasis, therapeutic response to microbiome-based degradation is likely influenced by diet, baseline hyperoxaluria severity, recent antibiotic exposure, and the functional structure of the existing gut microbiome [8,121]. Recent human colonization and multi-omics studies refine this interpretation. Fargue et al. showed that exogenously administered O. formigenes can colonize the gastrointestinal tract of healthy adults and reduce urinary oxalate excretion under controlled conditions [74]. Suryavanshi et al. further reported that baseline abundance of oxalate-degrading bacteria and frc/oxc genes is associated with stool oxalate, urinary oxalate, and variation in response to O. formigenes administration [11]. These findings support the conceptual framework presented in Figure 5: individuals with lower baseline oxalate-degrading capacity may have greater response potential, whereas individuals with higher baseline capacity may gain less additional benefit from microbial supplementation [11,74].

6.4. Why Clinical Translation Often Fails

Several factors may explain why oxalate-degrading probiotics do not consistently produce clinical benefit. First, colonization is a major limitation. O. formigenes is an oxygen-sensitive anaerobe with demanding growth requirements, and administered cells must survive gastric passage, bile exposure, oxygen stress, intestinal transit, and competition with resident microbiota [73,74]. Even when short-term fecal recovery occurs, long-term persistence may remain weak or variable [74]. Second, recipient microbiome structure can limit probiotic benefit. If the gut already contains active oxalate-degrading organisms, an introduced strain may provide little additional functional gain; conversely, individuals with lower baseline oxalate-degrading capacity may have greater response potential. This helps explain why baseline microbial function and community context may predict response better than probiotic dose alone [11,74].

Third, antibiotic exposure can disrupt oxalate-degrading communities. Human strains of O. formigenes are sensitive to several commonly used antibiotics, including macrolides, fluoroquinolones, tetracyclines, clindamycin, aminoglycosides, and metronidazole [105]. Oral antibiotic exposure has also been associated with increased odds of nephrolithiasis, supporting the need to consider antibiotic history when interpreting probiotic failure or designing clinical trials [106]. Fourth, dietary and host factors influence efficacy. Oxalate availability may support pathway induction, whereas dietary calcium can reduce soluble oxalate absorption by forming poorly soluble calcium oxalate complexes [18,23]. Fat malabsorption, bile acid disturbances, intestinal inflammation, and altered gut transit can increase soluble oxalate absorption and may create a less permissive niche for administered bacteria [23,97]. These factors indicate that probiotic therapy is unlikely to work consistently unless it is integrated with diet, intestinal physiology, and microbiome context.

Importantly, these clinical limitations should be interpreted according to hyperoxaluria subtype. In enteric or diet-associated hyperoxaluria, intestinal oxalate absorption and luminal oxalate availability are major contributors to urinary oxalate burden; therefore, gut-directed microbial degradation may have direct mechanistic relevance [23,120]. In contrast, primary hyperoxaluria is driven primarily by endogenous hepatic oxalate overproduction caused by inherited defects in glyoxylate metabolism [124,125]. Therefore, gut-restricted probiotic or microbiome-based approaches are unlikely to function as stand-alone treatments for primary hyperoxaluria and should be regarded as supportive or adjunctive strategies that complement established disease-specific management.

6.5. Strategies to Improve Microbiome-Based Therapy

Several strategies may improve the translational success of Frc–Oxc-targeted therapy. First, patient stratification should be incorporated into trial design. Patients should be grouped according to hyperoxaluria subtype, baseline urinary oxalate, dietary oxalate/calcium intake, recent antibiotic exposure, gut oxalate-degrading gene abundance, and fecal oxalate-degradation activity [6,11,17,73]. This approach would help identify patients most likely to benefit from microbial therapy instead of treating all calcium oxalate stone formers as a single homogeneous group. Second, synbiotic and niche-supporting approaches may improve engraftment and pathway activity. Combining oxalate-degrading bacteria with prebiotics, dietary modulation, or controlled oxalate/calcium balance may help create a gut environment that supports pathway induction, microbial persistence, and functional oxalate degradation [18,76,95,96]. This approach is more realistic than administering bacteria without modifying the ecological conditions required for their activity.

Third, improved delivery systems are needed. Protective formulations, anaerobic stabilization, and stress-tolerant delivery approaches may improve survival through the upper gastrointestinal tract and enhance delivery to intestinal sites where oxalate degradation is most relevant. For obligate anaerobes such as O. formigenes, formulation stability and viability during storage and transit remain especially important [73,104,115,126]. A qualitative comparison of major probiotic delivery strategies for oxalate-degrading microbial therapy is summarized in Figure 6, highlighting the relative advantages of conventional capsules, enteric-coated formulations, microencapsulation, anaerobic stabilization, defined consortia, and engineered live biotherapeutic products. Fourth, defined microbial consortia and engineered live biotherapeutics may offer advantages over single-strain probiotics, because microbiome engineering can expand genetically tractable gut microbes and enable rational design of strains or consortia with improved stability, targeted metabolic activity, and controlled therapeutic functions [119,127]. Defined consortia could combine oxalate degradation with ecological support functions, whereas engineered strains may provide more predictable oxalate-degrading activity. However, these approaches require careful safety evaluation, containment strategies, and long-term monitoring before clinical use [13,76,113]. Overall, the therapeutic potential of the Frc–Oxc pathway should be viewed as microbiome-based functional therapy rather than simple probiotic replacement. Successful clinical translation will likely require matching the right microbial function to the right patient, supported by diet, niche permissiveness, delivery technology, and longitudinal monitoring of urinary oxalate and stone-recurrence outcomes [11,23,113,128].

6.6. Safety and Efficacy in Special Populations

Oxalate-degrading probiotics have generally shown acceptable tolerability in the studied patient groups, although efficacy varies with host physiology, disease context, and baseline microbiome composition [11,13,121]. In idiopathic stone formers, probiotic interventions have generally shown acceptable tolerability, although urinary oxalate responses have been inconsistent across studies [25,121,129]. These outcomes may also be influenced by the baseline abundance of endogenous oxalate-degrading taxa [11]. However, patients with primary hyperoxaluria type 1 (PH1) generally have variable responses despite good tolerance due to difficulties in establishing optimal colonization of O. formigenes [123]. Greater therapeutic relevance may be expected in enteric hyperoxaluria, particularly in post-bariatric surgery settings, because intestinal oxalate absorption is a major contributor to urinary oxalate burden. In these patients, gut-directed microbial products may reduce luminal oxalate availability, although reported oxalate-lowering effects remain variable and should be interpreted cautiously across different study designs [7,30,120]. Evidence in patients with chronic kidney disease remains limited [130], while evidence in children, older adults, and patients with IBD is insufficient to draw population-specific conclusions. In summary, although oxalate-degrading probiotics are generally safe, their efficacy varies and is highly dependent on individual physiological and microbial characteristics [116,121,122].

7. Future Perspectives

The next generation of microbiome therapy for oxalate management should focus on function, not strain. The question should not be whether a probiotic strain has frc and oxc but whether the host’s gut is an appropriate environment for Frc–Oxc activity. This strategy suggests that approaches are needed to promote the intestinal environment consistent with pathway activation, persistence and oxalate degradation. This could involve diet modification, prebiotics, and removal of factors that downregulate oxalate-degrading activity. A further avenue is the design of new live biotherapeutics such as engineered strains or specific microbial communities, with enhanced oxalate-degrading activity, survival and persistence in the gut, and resistance to environmental stress.

Future studies should also emphasize functional patient stratification. Rather than relying only on taxonomic abundance or gene carriage, patients may be classified according to baseline oxalate-degrading capacity, ecological context, and disease subtype. In this setting, the proposed ONI may serve as a useful conceptual framework for integrating niche permissiveness with pathway-related capacity. Conceptually, ONI can be calculated as

ONI = 100 × (G × A × N × P × (1 − I))

where G represents the genetic capacity for oxalate degradation, reflected by the abundance or presence of key pathway genes such as frc, oxc, and oxlT. A represents pathway activity, which may be estimated through Frc/Oxc expression, enzyme activity, or experimentally measured oxalate-degradation capacity. N represents niche permissiveness, including intestinal pH, oxalate availability, anaerobic conditions, and transport energetics that support OxlT-mediated oxalate/formate exchange. P represents ecological persistence, including colonization stability, microbial survival, and compatibility with the resident gut community. I represent inhibitory pressure, including antibiotic exposure, bile acids, inflammation, unfavorable diet, and microbial competition. Each component is conceptually normalized from 0 to 1, producing a final ONI score ranging from 0 to 100. A higher ONI would indicate a gut environment more favorable for functional oxalate degradation, whereas a lower ONI would suggest that genetic potential may not translate into measurable activity. Although ONI is not yet clinically validated, it provides a hypothesis-generating framework for future studies using metagenomic, metatranscriptomic, enzyme-activity, fecal oxalate-degradation, urinary oxalate, dietary-control, and longitudinal stone-recurrence datasets. Overall, the most promising direction is a precise, ecology-informed strategy that combines microbial function, host environment, and targeted delivery to improve clinical consistency in hyperoxaluria and calcium oxalate kidney stone disease. Figure 7 provides a visual illustration of the future perspective section.

8. Conclusions

Frc–Oxc is an important route of oxalate degradation by microbes and a significant interaction between the gut microbiota and oxalate homeostasis. This pathway allows certain bacteria to break down oxalate in anaerobic conditions via the Frc/Oxc system and thus can possibly decrease intestinal absorption and the formation of calcium oxalate stones. However, gene carriage or abundance alone does not determine the stone-preventive potential of this pathway. Experimental and clinical evidence indicates that in vivo oxalate degradation is influenced by transport energetics, pH, microbial competition, colonization stability, diet, and antibiotic exposure. In this way, these multifactorial ecological and physiological constraints are seen in the variable efficacy of probiotic and microbiome-based therapies across studies and patient groups. To conclude, the Frc–Oxc pathway could be a therapeutic option in managing hyperoxaluria and oxalate stone disease, but this will need a strategy that includes the use of ecology and microbial delivery to activate and sustain the pathway. In this aspect, ONI should be regarded as a conceptual and hypothesis-generating framework rather than a clinically validated index. After future validation using metagenomic, metatranscriptomic, enzyme-activity, fecal oxalate-degradation, urinary oxalate, dietary-control, and longitudinal stone-recurrence datasets, ONI may help explain variability in treatment responses and guide the development of more predictable microbiome-based therapies for hyperoxaluria and calcium oxalate kidney stone disease.